KALA BIO Past Earnings Performance
Past criteria checks 0/6
KALA BIO has been growing earnings at an average annual rate of 9.6%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 2.6% per year.
Key information
9.6%
Earnings growth rate
30.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -2.6% |
| Return on equity | -562.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Kala Pharmaceuticals to execute reverse stock split
Oct 20Kala Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Staying Patient With Kala Pharmaceuticals
Aug 29The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts
Aug 10
Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?
Jul 07Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?
Apr 05Kala Pharmaceuticals, Inc. (NASDAQ:KALA): When Will It Breakeven?
Mar 08What Kind Of Investors Own Most Of Kala Pharmaceuticals, Inc. (NASDAQ:KALA)?
Feb 15How Many Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Shares Did Insiders Buy, In The Last Year?
Jan 25
If You Had Bought Kala Pharmaceuticals (NASDAQ:KALA) Stock A Year Ago, You Could Pocket A 77% Gain Today
Jan 04Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved
Dec 23The Play On Kala Pharmaceuticals
Dec 17Is Kala Pharmaceuticals (NASDAQ:KALA) Using Too Much Debt?
Dec 14How Much Did Kala Pharmaceuticals' (NASDAQ:KALA) CEO Pocket Last Year?
Nov 26Revenue & Expenses BreakdownBeta
How KALA BIO makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -42 | 21 | 19 |
| 30 Sep 23 | 0 | -46 | 22 | 17 |
| 30 Jun 23 | 0 | -9 | 26 | 17 |
| 31 Mar 23 | 3 | -26 | 44 | 17 |
| 31 Dec 22 | 4 | -45 | 65 | 18 |
| 30 Sep 22 | 6 | -80 | 83 | 17 |
| 30 Jun 22 | 8 | -137 | 99 | 14 |
| 31 Mar 22 | 9 | -145 | 104 | 13 |
| 31 Dec 21 | 11 | -143 | 105 | 12 |
| 30 Sep 21 | 12 | -126 | 108 | 12 |
| 30 Jun 21 | 11 | -126 | 106 | 13 |
| 31 Mar 21 | 9 | -113 | 93 | 16 |
| 31 Dec 20 | 6 | -104 | 81 | 18 |
| 30 Sep 20 | 5 | -95 | 69 | 21 |
| 30 Jun 20 | 5 | -90 | 60 | 25 |
| 31 Mar 20 | 6 | -91 | 62 | 26 |
| 31 Dec 19 | 6 | -94 | 65 | 27 |
| 30 Sep 19 | 5 | -98 | 65 | 30 |
| 30 Jun 19 | 3 | -90 | 58 | 30 |
| 31 Mar 19 | 1 | -81 | 48 | 31 |
| 31 Dec 18 | 0 | -67 | 35 | 29 |
| 30 Sep 18 | 0 | -53 | 26 | 26 |
| 30 Jun 18 | 0 | -47 | 20 | 26 |
| 31 Mar 18 | 0 | -44 | 15 | 27 |
| 31 Dec 17 | 0 | -42 | 11 | 29 |
| 30 Sep 17 | 0 | -39 | 7 | 30 |
| 30 Jun 17 | 0 | -39 | 6 | 31 |
| 31 Mar 17 | 0 | -38 | 8 | 29 |
| 31 Dec 16 | 0 | -33 | 8 | 25 |
| 30 Sep 16 | 0 | -30 | 7 | 22 |
| 30 Jun 16 | 0 | -25 | 8 | 16 |
| 31 Mar 16 | 0 | -18 | 5 | 13 |
| 31 Dec 15 | 0 | -17 | 5 | 11 |
| 30 Sep 15 | 0 | -17 | 4 | -2 |
| 30 Jun 15 | 0 | -17 | 4 | -1 |
| 31 Mar 15 | 0 | -18 | 4 | -1 |
| 31 Dec 14 | 0 | -19 | 4 | 0 |
| 31 Dec 13 | 0 | -11 | 3 | 0 |
Quality Earnings: KALA is currently unprofitable.
Growing Profit Margin: KALA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KALA is unprofitable, but has reduced losses over the past 5 years at a rate of 9.6% per year.
Accelerating Growth: Unable to compare KALA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KALA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: KALA has a negative Return on Equity (-562.35%), as it is currently unprofitable.